FCGR3A and neoplasm: When administered to JIMT-1 xenograft-bearing mCD16-/- hCD16A+ mice, MGAH22 exhibited enhanced anti-tumor activity compared with RES120 (Figure 4c), an activity attributable to the improved interaction between its optimized Fc domain and the human CD16A-158F (low-binding allele) receptor.